Treatment for Respiratory Tract Infections

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Respiratory Tract Infections+3 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial looks at how often three different viruses - RSV, influenza, and SARS-CoV-2 - cause respiratory infections in people at high risk for severe illness. It also looks at whether RSV is linked to hospitalization for respiratory illness.

Eligible Conditions
  • Respiratory Tract Infections

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

4 Primary · 18 Secondary · Reporting Duration: Up to 3 months

Day 1
Percentage of Participants Positive for Influenza Virus
Percentage of Participants Positive for Respiratory Syncytial Virus (RSV)
Percentage of Participants Positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Percentage of Participants Presenting with Clinically Relevant Disease at Screening and Diagnosed with or Without LRTD
Percentage of Participants Presenting with Complications at Screening and Diagnosed with or Without LRTD
Up to 3 months
Orthomyxoviridae
Severe Acute Respiratory Syndrome
Number of Participants with Relative Risk of Acute Respiratory Infections (ARI)- related Hospitalization in Participants Positive for RSV with Lower Respiratory Tract Disease (LRTD) or Without LRTD
Percentage of Participants Positive for Influenza Virus Reporting ARI-related Hospitalizations During the Study Period
Percentage of Participants Positive for RSV Reporting ARI-related Hospitalizations During the Study Period
Percentage of Participants Positive for SARS-CoV-2 Reporting ARI-related Hospitalizations During the Study Period
Percentage of Participants Reporting ARI- related Clinically Relevant Disease During the Follow-up Period and Diagnosed with or Without LRTD
Percentage of Participants Reporting ARI- related Complications During the Follow-up Period and Diagnosed with or Without LRTD
Time to ARI- related Complications During the Follow-up Period in Participants Positive for Influenza Virus
Time to ARI- related Complications During the Follow-up Period in Participants Positive for RSV
Time to ARI- related Complications During the Follow-up Period in Participants Positive for SARS-CoV-2
Time to ARI- related Hospitalization in Participants Positive for Influenza Virus
Time to ARI- related Hospitalization in Participants Positive for RSV
Time to ARI- related Hospitalization in Participants Positive for SARS-CoV-2
Orthomyxoviridae
Time to ARI-related Clinically Relevant Disease During the Follow-up Period in Participants Positive for RSV
Time to ARI-related Clinically Relevant Disease During the Follow-up Period in Participants Positive for SARS-CoV-2

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

0 Treatment Group

2960 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase < 1

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 months

Who is running the clinical trial?

Janssen Research & Development, LLCLead Sponsor
918 Previous Clinical Trials
6,323,496 Total Patients Enrolled
2 Trials studying Respiratory Tract Infections
90 Patients Enrolled for Respiratory Tract Infections
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
707 Previous Clinical Trials
3,896,444 Total Patients Enrolled
2 Trials studying Respiratory Tract Infections
90 Patients Enrolled for Respiratory Tract Infections

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be able to read, understand, and complete questionnaires.
You must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: November 20th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.